Type 2 diabetes nephropathy
Conditions
Sponsors
Northern Jiangsu People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All participants were required to meet the 1999 WHO diagnostic criteria for diabetes mellitus: those with typical diabetic symptoms (dry mouth, excessive drinking and urination, unexplained weight loss) met one of the criteria: (1) random blood glucose >=11.1 mmol/L; (2) fasting plasma glucose >=7.0 mmol/L; (3) plasma glucose >=11.1 mmol/L after two hours of oral glucose tolerance test; those with no typical symptoms need to be measured again on a different day. Diabetic nephropathy is diagnosed according to the 2021 Chinese Clinical Guidelines for the Prevention and Treatment of Diabetic Kidney Disease: at least one of the following: (1) eGFR less than 60 ml-min-1-(1.73 m2)-1 for more than 3 months; (2) urinary albumin/creatinine ratio more than 30 mg/g for more than 3 months; and (3) renal biopsy consistent with the pathologic changes of DKD. The etiology of renal disease was considered to be non-diabetic in the presence of the following conditions: (1) type 1 diabetes mellitus with a short duration of illness (<10 years) or without comorbid diabetic retinopathy; (2) a rapid decline in eGFR; (3) a rapid increase in urinary proteins or the development of a nephrotic syndrome; (4) refractory hypertension; (5) the presence of active urinary sediment erythrocytes, leukocytes, or cellular tubular patterns; and (6) the comorbidity with other systemic signs or symptoms of disease; (7) a decrease in eGFR greater than 30% within 2 to 3 months after administration of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists; and (8) abnormal renal ultrasound findings.
Exclusion criteria
Exclusion criteria: Other primary renal diseases; other types of diabetes except type 2 diabetes mellitus; acute complications of diabetes mellitus such as diabetic ketoacidosis, hyperglycemic hyperosmolar syndrome, diabetic lactic acidosis; severe infections and other stress conditions; autoimmune system, hematologic disorders, or malignant tumors; cardiac insufficiency, hepatic abnormalities, and severe cardiovascular and cerebral vascular disorders; severe psychiatric disorders or mental retardation; and the use of other aldosterone receptor antagonist patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SEMA3C; | — |
Secondary
| Measure | Time frame |
|---|---|
| c peptide; | — |
Countries
China
Contacts
Public ContactZhenwen Zhang
Northern Jiangsu People's Hospital
Outcome results
None listed